Affordable Access

Access to the full text

Identification of a small molecule that facilitates the differentiation of human iPSCs/ESCs and mouse embryonic pancreatic explants into pancreatic endocrine cells

Authors
  • Kondo, Yasushi1, 2
  • Toyoda, Taro1
  • Ito, Ryo1, 2
  • Funato, Michinori1
  • Hosokawa, Yoshiya1
  • Matsui, Satoshi1
  • Sudo, Tomomi1
  • Nakamura, Masahiro1
  • Okada, Chihiro1, 3
  • Zhuang, Xiaotong2
  • Watanabe, Akira1
  • Ohta, Akira1
  • Inagaki, Nobuya2
  • Osafune, Kenji1
  • 1 Kyoto University, Center for iPS Cell Research and Application (CiRA), 53 Kawahara-cho, Shogoin, Sakyo-ku, Kyoto, 606-8507, Japan , Kyoto (Japan)
  • 2 Kyoto University, Department of Diabetes, Endocrinology and Nutrition, Shogoin, Sakyo-ku, Kyoto, Japan , Kyoto (Japan)
  • 3 Mitsubishi Space Software Co., Ltd, 5-4-36, Tsukaguchi-honmachi, Amagasaki, Hyogo, Japan , Amagasaki (Japan)
Type
Published Article
Journal
Diabetologia
Publisher
Springer-Verlag
Publication Date
May 22, 2017
Volume
60
Issue
8
Pages
1454–1466
Identifiers
DOI: 10.1007/s00125-017-4302-7
Source
Springer Nature
Keywords
License
Yellow

Abstract

Aims/hypothesisPancreatic beta-like cells generated from human induced pluripotent stem cells (hiPSCs) or human embryonic stem cells (hESCs) offer an appealing donor tissue source. However, differentiation protocols that mainly use growth factors are costly. Therefore, in this study, we aimed to establish efficient differentiation protocols to change hiPSCs/hESCs to insulin (INS)+ cells using novel small-molecule inducers.MethodsWe screened small molecules that increased the induction rate of INS+ cells from hESC-derived pancreatic and duodenal homeobox 1 (PDX1)+ pancreatic progenitor cells. The differentiation protocol to generate INS+ cells from hiPSCs/hESCs was optimised using hit compounds, and INS+ cells induced with the compounds were characterised for their in vitro and in vivo functions. The inducing activity of the hit compounds was also examined using mouse embryonic pancreatic tissues in an explant culture system. Finally, RNA sequencing analyses were performed on the INS+ cells to elucidate the mechanisms of action by which the hit compounds induced pancreatic endocrine differentiation.ResultsOne hit compound, sodium cromoglicate (SCG), was identified out of approximately 1250 small molecules screened. When SCG was combined with a previously described protocol, the induction rate of INS+ cells increased from a mean ± SD of 5.9 ± 1.5% (n = 3) to 16.5 ± 2.1% (n = 3). SCG induced neurogenin 3-positive cells at a mean ± SD of 32.6 ± 4.6% (n = 3) compared with 14.2 ± 3.6% (n = 3) for control treatment without SCG, resulting in an increased generation of endocrine cells including insulin-producing cells. Similar induction by SCG was confirmed using mouse embryonic pancreatic explants. We also confirmed that the mechanisms of action by which SCG induced pancreatic endocrine differentiation included the inhibition of bone morphogenetic protein 4 signalling.Conclusions/interpretationSCG improves the generation of pancreatic endocrine cells from multiple hiPSC/hESC lines and mouse embryonic pancreatic explants by facilitating the differentiation of endocrine precursors. This discovery will contribute to elucidating the mechanisms of pancreatic endocrine development and facilitate cost-effective generation of INS+ cells from hiPSCs/hESCs.Data availabilityThe RNA sequencing data generated during the current study are available in the Gene Expression Omnibus (www.ncbi.nlm.nih.gov/geo) with series accession number GSE89973.

Report this publication

Statistics

Seen <100 times